News
Bendamustine-Rituximab Doubles Progression-Free Survival in Indolent Lymphomas
- Author:
- Mary Jo M. Dales
News
NSCLC: FDA Approves Crizotinib, Companion Diagnostic Test
- Author:
- Mary Jo M. Dales
News
Many Cancer Patients Face Crippling Costs
- Author:
- Mary Jo M. Dales
Major Finding: First-time bankruptcy filings averaged 0.5% of patients at 1 year after cancer diagnosis and 1.9% at 5 years after diagnosis....
News
Many Cancer Patients Face Crippling Costs
- Author:
- Mary Jo M. Dales
Major Finding: First-time bankruptcy filings averaged 0.5% of patients at 1 year after cancer diagnosis and 1.9% at 5 years after diagnosis....
News
Many Cancer Patients Face Crippling Costs
- Author:
- Mary Jo M. Dales
Major Finding: First-time bankruptcy filings averaged 0.5% of patients at 1 year after cancer diagnosis and 1.9% at 5 years after diagnosis....
News
Rich Patients With Poor Prognosis Cancers Get More Treatment
- Author:
- Mary Jo M. Dales
Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and...
News
Rich Patients With Poor Prognosis Cancers Get More Treatment
- Author:
- Mary Jo M. Dales
Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and...
News
Rich Patients With Poor Prognosis Cancers Get More Treatment
- Author:
- Mary Jo M. Dales
Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and...
News
Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma
- Author:
- Mary Jo M. Dales
Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...
News
Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma
- Author:
- Mary Jo M. Dales
Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...
Video
ASCO: Ipilimumab Plus Dacarbazine Prolongs Metastatic Melanoma Survival
- Author:
- Mary Jo M. Dales
Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...
News
Screening Does Not Reduce Ovarian Cancer Mortality
- Author:
- Mary Jo M. Dales
Major Finding: Among women who underwent screening with the CA 125 blood test and transvaginal ultrasound, 118 died of ovarian cancer, whereas 100...
News
Screening Does Not Reduce Ovarian Cancer Mortality
- Author:
- Mary Jo M. Dales
Major Finding: Among women who underwent screening with the CA 125 blood test and transvaginal ultrasound, 118 died of ovarian cancer, whereas 100...
News
Menactra Approved for Children 9 Months and Older
- Author:
- Mary Jo M. Dales
News
There's a New Look for Internal Medicine News
- Author:
- Mary Jo M. Dales